Logo Image
|Articles|January 17, 2011

Ecron Acunova CRO Expands its Clinical Research Center for Drug Development

Ecron Acunov announced expansion of their Mangalore Clinical Pharmacology Unit to a 80 bed facility. The Research Center was dedicated by Dr. Ramdas M Pai, Chancellor, Manipal University.

This expansion caters to the growing needs of its global clients in Pharmaco-Kinetic and Pharmaco Dynamic studies. This takes total bed capacity to 176 units in research centers at Mangalore, Manipal, and Bangalore. Drug research involves analyzing the activity of the drug in plasma using spectroscopy. Highly sophisticated spectrometers have been added. Speaking on the occasion Dr. Ramdas Pai said, "I commend the safe conduct of studies for Indian and global companies, leveraging the scientific and clinical talent of India. It is heartening to note that studies conducted at the center, got US FDA approval, leading to launch of drugs for treatment of HIV, cancer etc."

Related to this article

View more
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
Read more
What the Epilepsy Community Has Taught Us About Trial Feasibility
What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.
Read more